Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Trevi Therapeutics, Inc. (TRVI) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 8-K Quarterly results
Docs: "Trevi Therapeutics Announces Second Quarter 2023 Financial Results and Provides Business Update Plans to initiate three clinical studies in chronic cough indications for later this year remain on track Data from Phase 2 CANAL trial of chronic cough in patients with idiopathic pulmonary fibrosis published in NEJM Evidence Management to host a conference call and webcast today at 4:30 p.m. EDT New Haven, Conn., August 10, 2023 – Trevi Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ for difficult to treat patients with chronic cough in idiopathic pulmonary fibrosis , other chronic cough indications, and prurigo nodularis, today announced financial results for the quarter ended June 30, 2023, as well as provided business updates. ..."
06/29/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders...
Docs: "TREVI THERAPEUTICS, INC. By: /s/ Jennifer Good Name: Jennifer Good Title: Chief Executive Officer [Signature Page to Certificate of Amendment]"
05/11/2023 8-K Quarterly results
Docs: "Trevi Therapeutics Announces First Quarter 2023 Financial Results and Provides Business Update Initiating three clinical studies in chronic cough indications later this year Received Notice of Allowance for key U.S. patent for the use of oral nalbuphine ER for the treatment of chronic cough in idiopathic pulmonary fibrosis Management to host a conference call and webcast today at 4:30 p.m. EDT New Haven, Conn., May 11, 2023 – Trevi Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ for difficult to treat patients with chronic cough in idiopathic pulmonary fibrosis , other chronic cough indications and prurigo nodularis , today announced financial results for the quarter ended March 31, 2023, as well as provided business updates. ..."
04/14/2023 8-K Quarterly results
03/16/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Trevi Therapeutics Announces Fourth Quarter and Year End 2022 Financial Results and Provides Business Update Multiple trial initiations planned for 2023 to progress Haduvio in chronic cough indications Management to host a conference call and webcast today at 4:30 p.m. EDT New Haven, Conn., March 16, 2023 – Trevi Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis and other chronic cough indications, and for the treatment of prurigo nodularis, today announced financial results for the quarter and year ended December 31, 2022, as well as provided business updates. "Following the very encouraging results from our Phase 2 CANAL trial in IPF chronic co..."
11/10/2022 8-K Quarterly results
Docs: "Trevi Therapeutics Announces Third Quarter 2022 Financial Results and Provides Business Update Management to host a conference call and webcast today at 4:30 p.m. EDT"
09/23/2022 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Underwriting Agreement, by and among the Company and SVB Securities LLC, Stifel, Nicolaus & Company, Incorporated and Oppenheimer & Co. Inc",
"Form of Pre-Funded Warrant",
"Opinion of Wilmer Cutler Pickering Hale and Dorr LLP",
"Trevi Therapeutics Announces Pricing of $55 Million Public Offering New Haven, Conn., September 23, 2022 - Trevi Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing an investigational therapy, Haduvio ™ for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis and the treatment of prurigo nodularis , today announced the pricing of its underwritten public offering of 14,252,670 shares of its common stock at a public offering price of $1.93 per share, and, to certain investors in lieu of common stock, pre-funded warrants to purchase 14,247,330 shares of common stock at a price of $1.929 per pre-funded warrant, for total proceeds of approximately $55 million, before deducting underwriting discounts and commissions and expenses payable by Trevi. The..."
09/19/2022 8-K Investor presentation
Docs: "2 6 3 7 8 9 10"
08/11/2022 8-K Quarterly results
06/29/2022 8-K Quarterly results
06/23/2022 8-K Quarterly results
05/13/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
04/07/2022 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...
Docs: "Form of Pre-Funded Warrant",
"Securities Purchase Agreement, by and among the Registrant and the Purchasers named therein",
"Registration Rights Agreement, by and among the Registrant and the Purchasers named therein",
"Third Amendment to Loan and Security Agreement, by and between Silicon Valley Bank and the Registrant",
"Trevi Therapeutics Announces $55 Million Private Placement Priced At-the-Market"
03/17/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Trevi Therapeutics Announces Fourth Quarter and Year End 2021 Financial Results and Business Update Interim Analysis in Phase 2 CANAL Trial Showed Primary Efficacy Endpoint of Cough Reduction in Idiopathic Pulmonary Fibrosis was Highly Statistically Significant"
03/16/2022 8-K Other Events  Interactive Data
02/24/2022 8-K Quarterly results
02/01/2022 8-K Other Events  Interactive Data
01/14/2022 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
01/05/2022 8-K Other Events  Interactive Data
11/10/2021 8-K Quarterly results
Docs: "Trevi Therapeutics Announces Third Quarter 2021 Financial Results and Business Update Phase 2b/3 PRISM Trial Approximately 90% Enrolled, Top-Line Data Readout Expected First Half of 2022"
10/19/2021 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...
Docs: "Form of 7-Year Warrant",
"Form of 3.5-Year Warrant",
"Form of Securities Purchase Agreement",
"Form of Registration Rights Agreement"
10/01/2021 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Form of Pre-Funded Warrant",
"Form of 7-Year Common Stock Warrant",
"Form of 3.5-Year Common Stock Warrant",
"Form of Securities Purchase Agreement",
"Form of Registration Rights Agreement",
"Trevi Therapeutics Announces $11.8 Million Private Placement Priced At-the-Market"
08/12/2021 8-K Quarterly results
Docs: "Phase 2b/3 PRISM trial of Haduvio for severe pruritus in patients with PN o Approximately 285, or 80%, of planned subjects have enrolled ▪ Enrollment expected to be completed by the end of 2021 o Top-line data readout expected in the first half of 2022 • Phase 2 CANAL trial of Haduvio for chronic cough in patients with IPF o Ongoing recruitment and screening taking place at multiple sites in the UK o Top-line data readout expected in the first half of 2022 • Expanded leadership team to support the growth of the Company Second Quarter 2021 Financial Highlights Cash position: As of June 30, 2021, the Company had total cash and cash equivalents of $36.4 million, compared to $45.0 million as of December 31, 2020. Research and development expenses: R&D expenses for the second quarter of 2..."
08/09/2021 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
07/09/2021 8-K Quarterly results
07/06/2021 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "First Amendment to Loan and Security Agreement, by and between Silicon Valley Bank and the Registrant"
06/21/2021 8-K Quarterly results
06/21/2021 8-K Quarterly results
05/13/2021 8-K Quarterly results
04/02/2021 8-K Quarterly results
03/25/2021 8-K Quarterly results
03/22/2021 8-K Quarterly results
11/12/2020 8-K Quarterly results
Docs: "Phase 2b/3 PRISM trial of Haduvio for severe pruritus in patients with prurigo nodularis: The Company has enrolled approximately 190 subjects in the trial and reaffirms its guidance that it expects to complete enrollment in the third quarter of 2021 and to report top-line data in the fourth quarter of 2021. • Phase 2 trial of Haduvio for chronic cough in patients with idiopathic pulmonary fibrosis : The Company resumed screening and enrolling patients in the trial following the pause in the trial due to COVID-19. The Company amended the study protocol to require fewer in-person visits by subjects as well as fewer procedures in order to facilitate the completion of the trial in an at-risk patient population for COVID-19. Additionally, the Company is assessing additional study sites i..."
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy